57 results on '"Stilgenbauer, Stephan"'
Search Results
2. The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network
3. Venetoclax resistance in acute lymphoblastic leukemia is characterized by increased mitochondrial activity and can be overcome by co-targeting oxidative phosphorylation
4. Impairment of α-tubulin and F-actin interactions of GJB3 induces aneuploidy in urothelial cells and promotes bladder cancer cell invasion
5. SOP – Darmpassagestörung in der Palliativmedizin
6. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial
7. Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
8. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
9. Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis
10. Loss of ORP3 induces aneuploidy and promotes bladder cancer cell invasion through deregulated microtubule and actin dynamics
11. Profile of the multicenter cohort of the German Cancer Consortium’s Clinical Communication Platform
12. Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic
13. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome
14. Molecular map of chronic lymphocytic leukemia and its impact on outcome
15. Kapazität der onkologischen Versorgung in deutschen onkologischen Spitzenzentren während der ersten 2 Jahre der COVID-19-Pandemie
16. Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
17. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial
18. The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia
19. Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients
20. Proteogenomics refines the molecular classification of chronic lymphocytic leukemia
21. Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escape
22. EOMES is essential for antitumor activity of CD8+ T cells in chronic lymphocytic leukemia
23. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations
24. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials
25. EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia
26. Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas
27. Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study
28. Insertion site of central venous catheter correlates with catheter-related infectious events in patients undergoing intensive chemotherapy
29. Renal AA amyloidosis leading to early diagnosis and treatment of takayasu arteritis: a case report and review of the literature
30. Protection strategy against outbreak of COVID-19 at a tertiary hematology-oncology: strengths and pitfalls
31. Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia
32. Killer immunoglobulin-like receptor 2DS5 is associated with recovery from coronavirus disease 2019
33. Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potential
34. Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial
35. COVID-19 among fit patients with CLL treated with venetoclax-based combinations
36. Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group
37. Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy
38. Elevated Hedgehog activity contributes to attenuated DNA damage responses in aged hematopoietic cells
39. Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study
40. The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab
41. Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL
42. Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia
43. Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational study
44. Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia
45. PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia
46. CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia
47. Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues
48. DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy
49. Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL
50. Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.